This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)

This study has been completed.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: February 10, 2012
Last updated: March 22, 2016
Last verified: March 2016
This study will assess the safety and efficacy of LFG316 in patients with age related macular degeneration.

Condition Intervention Phase
Neovascular Age-elated Macular Degeneration (Wet AMD) Exudative Macular Degeneration Drug: LFG316 Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Sham-controlled, Repeat-dose Study to Assess the Safety, Tolerability, Serum Pharmacokinetics, and Efficacy of Intravitreal LFG316 in Patients With Neovascular Age-related Macular Degeneration

Resource links provided by NLM:

Further study details as provided by Novartis ( Novartis Pharmaceuticals ):

Primary Outcome Measures:
  • Number of anti-Vascular Endothelial Growth Factor (anti-VEGF) retreatments vs time [ Time Frame: Day 1 to 113 ]
    Number or retreatments with anti-VEGF treatments will be recorded

Secondary Outcome Measures:
  • The proportion of patients in the study that requires at least one treatment of anti-VEGF medication. [ Time Frame: Day 1 and 113 ]
    Number or retreatments with anti-VEGF treatments will be recorded

  • Effect of LFG316 on visual acuity [ Time Frame: Day 1 and 113 ]
    Early Treatment Diabetic Retinopathy Study" (ETDRS best corrected visual acuity measured under ESTDRS conditions Number of letters correctly read will be recorded.

  • Effect of LFG316 on central retinal thickness and choroidal neovascular membrane area, and drusen area/volume where applicable [ Time Frame: Day 1 , Day 85 and Day 113 (starting from the day of first IVT injection until end of study) ]
    Summary statistics of these variables will be provided by treatment and visit/time. Treatment effect will be assessed by comparison of mean change from baseline to Day 85.

  • Serum concentrations of total LFG316 versus time [ Time Frame: Days 1, 8, 15, 29, 43, 57, 71, 85 and 113 ]
    Blood samples will be collected

  • Number of patients with adverse events [ Time Frame: Day 113 ]
    Adverse events will be determined based on descriptive analyses of vital signs, electrocardiogram (ECG) evaluation, and clinical safety laboratory evaluations. All abnormalities will be flagged and summary statistics will be provided by treatment and visit/time.

Enrollment: 43
Study Start Date: February 2012
Study Completion Date: July 2013
Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: LFG316 Drug: LFG316
Sham Comparator: Sham Drug: Placebo
Placebo will be administered as sham injections. Sham injections will involve placement of the syringe hub against the sclera, without use of a needle.


Ages Eligible for Study:   55 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Best corrected visual acuity (ETDRS scale) of 60 letters or less in the study eye.
  • An active choroidal neovascular membrane attributable to neovascular AMD in at least one eye.
  • History of treatment (at any time) with at least 3 doses of anti-VEGF therapy in the study eye.

Exclusion Criteria:

  • History of recurrent non-response to anti-VEGF therapy in the study eye.
  • In the study eye, retinal disease other than AMD (benign conditions of the vitreous and peripheral retina are not exclusionary).
  • Choroidal neovascularization due to a cause other than AMD.
  • In the study eye, media opacity that, in the investigator's opinion, could interfere with conduct of the study.
  • History of infectious uveitis or endophthalmitis in either eye.
  • Any of the following treatments to the study eye within 28 days prior to dosing: ranibizumab, bevacizumab, pegaptanib or other VEGF inhibitor.
  • Any of the following within 90 days prior to dosing: photodynamic therapy or laser photocoagulation in the study eye; intravitreal steroid in the study eye; or intraocular surgery (including cataract surgery) in the study eye
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01535950

United States, Arizona
Novartis Investigative Site
Tuscon, Arizona, United States, 85704-5614
United States, California
Novartis Investigative Site
Torrance, California, United States, 90503
United States, Florida
Novartis Investigative Site
Fort Myers, Florida, United States, 33912-7125
United States, Maryland
Novartis Investigative Site
Baltimore, Maryland, United States, 21237-4350
United States, South Carolina
Novartis Investigative Site
West Columbia, South Carolina, United States, 29169
United States, Texas
Novartis Investigative Site
Abilene, Texas, United States, 79606
Novartis Investigative Site
Forth Worth, Texas, United States, 76104
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Responsible Party: Novartis Pharmaceuticals Identifier: NCT01535950     History of Changes
Other Study ID Numbers: CLFG316A2202
Study First Received: February 10, 2012
Last Updated: March 22, 2016

Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Age-related macular degeneration
intravitreal, neovascular
anti-vascular endothelial growth factor
wet AMD
Macular degeneration

Additional relevant MeSH terms:
Macular Degeneration
Wet Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases processed this record on August 18, 2017